



National Radiology Data Registry

Facility Report, Sep 2021

Public Facility
(Facility ID: 100853)



nrdr.acr.org



This page is intentionally blank.

Lung Cancer Screening Registry Report from the American College of Radiology

We are pleased to release the Jan-Sep 2021 quarterly Lung Cancer Screening Registry reports. The PDF report contains the following:

Section 1: Facility level data, 2021

This section provides a list of LCSR measures calculated from data submitted during Jan-Sep 2021. We provide a comparison of your measures with the LCSR registry and similar facilities in terms of facility type, location and census division. Section 1 is provided only for those facilities that have submitted data during 2021.

Section 2: Facility level data, 2020

This section provides a list of LCSR measures calculated from data submitted during Jan-Dec 2020. We provide a comparison of your measures with the LCSR registry and similar facilities in terms of facility type, location and census division. Section 2 is provided only for those facilities that submitted data during 2020.

Demographic Data


The bar charts describe demographic data of all the facilities that contributed data during 2020 and 2021.

Maintenance of Certification (MOC):Practice Quality Improvement (PQI).

We have listed the physicians participating in LCSR at your facility and their NPI's.

We exclude exams without NPI information for the interpreting radiologist as it is a required field for CMS submission, in our role as a CMS approved registry.

LCSR Facilities



Census Division	Color	Division Name
Blue	Blue	New England Division
Brown	Brown	West North Central Division
Light Blue	Light Blue	West South Central Division
Red	Red	Middle Atlantic Division
Purple	Purple	South Atlantic Division
Teal	Teal	East North Central Division
Yellow-Green	Yellow-Green	East South Central Division
Pink	Pink	Mountain Division
Orange	Orange	Pacific Division

Black dots indicate LCSR facilities that contributed data for this report

LCSR Measure Definitions

Measure	Description
Appropriateness of screening by USPSTF criteria	Percent of screening population who are adults aged 55 to 80 years, have a 30 pack-year smoking history, and currently smoke or have quit within the past 15 years.
NOTE:	The updated USPSTF criteria from March 2021 will be implemented in 2022 Q1 reports onward.
Smoking cessation offered	Percent of patients who are offered smoking cessation guidance.
Smoking cessation offered among current smokers	Percent of current smokers who are offered smoking cessation guidance.
Radiation exposure 1 Mean CT DIvol - overall	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed.
Radiation exposure 1 Mean CT DIvol underweight (BMI <18.5)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on underweight patients (BMI<18.5).
Radiation exposure 1 Mean CT DIvol normal (BMI of 18.5–24.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on normal weight patients (BMI of 18.5-24.9).
Radiation exposure 1 Mean CT DIvol overweight (BMI of 25–29.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on overweight patients (BMI of 25-29.9).
Radiation exposure 1 Mean CT DIvol obese (BMI of 30 or more)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on obese patients (BMI of 30 or more).
Radiation exposure 1 Mean CT DIvol obese class I (BMI of 30-34.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on class I obese patients (BMI of 30-34.9).
Radiation exposure 1 Mean CT DIvol obese class II (BMI of 35-39.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on class II obese patients (BMI of 35-39.9).
Radiation exposure 1 Mean CT DIvol obese class III (BMI of 40 or greater)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on class III obese patients (BMI of 40 or greater).
Radiation exposure 1 Mean CT DIvol - routine chest exams	Mean Volumetrics CT Dose Index (CT DIvol) across routine chest exams performed.
Radiation exposure 1 Mean CT DIvol - other than routine chest exams	Mean Volumetrics CT Dose Index (CT DIvol) across other than routine chest exams performed.
Radiation exposure (DLP)	Mean Dose Length Product (DLP) across all screening exams performed.
Radiation exposure 2 Mean DLP underweight (BMI <18.5)	Mean Dose Length Product (DLP) across all screening exams performed on underweight patients (BMI<18.5).




LCSR Measure Definitions

Measure	Description
Radiation exposure 2 Mean DLP normal (BMI of 18.5–24.9)	Mean Dose Length Product (DLP) across all screening exams performed on normal weight patients (BMI of 18.5-24.9).
Radiation exposure 2 Mean DLP overweight (BMI of 25–29.9)	Mean Dose Length Product (DLP) across all screening exams performed on overweight patients (BMI of 25-29.9).
Radiation exposure 2 Mean DLP obese (BMI of 30 or more)	Mean Dose Length Product (DLP) across all screening exams performed on obese patients (BMI of 30 or more).
Radiation exposure 2 Mean DLP obese class I (BMI of 30-34.9)	Mean Dose Length Product (DLP) across all screening exams performed on class I obese patients (BMI of 30-34.9).
Radiation exposure 2 Mean DLP obese class II (BMI of 35-39.9)	Mean Dose Length Product (DLP) across all screening exams performed on class II obese patients (BMI of 35-39.9).
Radiation exposure 2 Mean DLP obese class III (BMI of 40 or greater)	Mean Dose Length Product (DLP) across all screening exams performed on class III obese patients (BMI of 40 or greater).
Radiation exposure 2 Mean DLP - routine chest exams	Mean Dose Length Product (DLP) across routine chest exams performed.
Radiation exposure 2 Mean DLP - other than routine chest exams	Mean Dose Length Product (DLP) across other than routine chest exams performed.
Lung Cancer Screening Abnormal Interpretation Rate (Recall Rate)	Percent of screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy).
Lung Cancer Screening Abnormal Interpretation Rate (Recall Rate) during	Percent of baseline screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy). Percent of annual screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy).
Lung Cancer Screening Cancer Detection Rate (CDR)	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 months.
CDR for prevalent cancers, detected at baseline exam	Number per 1000 baseline (first visit) screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 mo
CDR for incident cancers, detected at annual exam	Number per 1000 annual (not baseline) screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 mon
CDR for stage 0	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 0 within 12 months.

LCSR Measure Definitions

Measure	Description
CDR for stage IA, IA1, IA1, IA3, IB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 1 within 12 months.
CDR for stage IIA, IIB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 2 within 12 months.
CDR for stage IIIA, IIIB, IIIC	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 3 within 12 months.
CDR for stage IV, IVA, IVB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 4 within 12 months.
CDR for unknown stage	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of unknown cancer stage within 12 months.
CDR for presumptive stage	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a non-histology diagnosis of cancer within 12 months.
PPV1	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months.
PPV1 for lung cancers detected on percutaneous biopsies	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on percutaneous
PPV1 for lung cancers detected on bronchoscopies	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on bronchoscopy
PPV1 for surgically detected lung cancers	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on surgical in
PPV2a	Percent of screening exams that had a Lung-RADS assessment category of 3, 4a (typically associated with additional CT recommendation or PET/CT recommendation) that
PPV2b	Percent of screening exams that had a Lung-RADS assessment category of 4B or 4X (typically associated with biopsy recommendation) that had a tissue diagnosis of can
PPV3	Percent of screening exams that had a Lung-RADS assessment category of 4B or 4X (typically associated with biopsy recommendation) and with record of biopsy performe

LCSR Facility Characteristics : 2020-2021



Section 1 Facility Report: Preliminary data on exams performed during Jan-Sep 2021

Facility 100853 National Comparison
Jan-Sep 2021

		2021				2020	
Measure		Your Facility (100853)		All LCSR		All LCSR	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	176790	.	589288	.	659558
Appropriateness of screening by USPSTF criteria (%)		88.08	155716 / 176790	87.99	518487 / 589288	91.19	601462 / 659558
Smoking cessation counselling offered (%)		73.74	130357 / 176790	73.71	434393 / 589288	75.24	496278 / 659558
	counselling offered among current smokers (%)	80.02	82660 / 103296	79.98	276548 / 345781	81.73	307414 / 376131
Radiation exposure - Mean CT DIvol	Overall (mGy)	3.44	NA / 175273	3.45	NA / 583973	3.34	NA / 650910
	underweight (BMI <18.5)(mGy)	2.44	NA / 4786	2.52	NA / 15897	2.47	NA / 15753
	normal (BMI of 18.5-24.9)(mGy)	2.76	NA / 40481	2.73	NA / 135147	2.61	NA / 154108
	overweight (BMI of 25-29.9)(mGy)	3.20	NA / 54457	3.23	NA / 181425	3.14	NA / 205649
	obese (BMI 30 or more)(mGy)	4.14	NA / 65888	4.19	NA / 219441	4.08	NA / 241145
	obese class I (BMI of 30-34.9)(mGy)	3.80	NA / 36783	3.85	NA / 122468	3.76	NA / 137061
	obese class II (BMI of 35-39.9)(mGy)	3.93	NA / 16688	3.99	NA / 56397	3.76	NA / 61708
	obese class III (BMI of 40 or greater)(mGy)	4.27	NA / 12417	4.31	NA / 40576	4.35	NA / 42376
	routine chest exam (mGy)	4.63	NA / 1672	4.79	NA / 5500	4.67	NA / 9229
	low dose CT chest exam (mGy)	3.43	NA / 172604	3.44	NA / 575139	3.33	NA / 637989
Radiation exposure - Mean DLP	Overall	93.90	NA / 175264	94.20	NA / 584013	94.67	NA / 651692
	underweight (BMI <18.5)(mGy-cm)	71.20	NA / 4786	70.71	NA / 15902	70.50	NA / 15790
	normal (BMI of 18.5-24.9)(mGy-cm)	75.83	NA / 40482	75.96	NA / 135180	76.77	NA / 154337
	overweight (BMI of 25-29.9)(mGy-cm)	88.00	NA / 54459	88.89	NA / 181469	89.30	NA / 205891
	obese (BMI of 30 or more)(mGy-cm)	111.28	NA / 65877	111.40	NA / 219438	112.19	NA / 241382
	obese class I (BMI of 30-34.9)(mGy-cm)	103.43	NA / 36775	103.76	NA / 122476	1.00	NA / 137212
	obese class II (BMI of 35-39.9)(mGy-cm)	115.47	NA / 16682	115.62	NA / 56385	1.00	NA / 61760
	obese class III (BMI of 40 or greater)(mGy-cm)	128.00	NA / 12420	127.68	NA / 40577	129.71	NA / 42410
	routine chest exam (mGy-cm)	162.30	NA / 1676	162.93	NA / 5514	141.85	NA / 9255
	low dose CT chest exam (mGy-cm)	93.19	NA / 172592	93.49	NA / 575168	94.00	NA / 638746
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	13.59	24032 / 176790	13.64	80355 / 589288	13.57	89526 / 659558
	Abnormal Interpretation Rate, at baseline exam (%)	16.51	14539 / 88036	16.58	48666 / 293476	16.58	52230 / 315095

Facility 100853 National Comparison
Jan-Sep 2021

		2021				2020	
Measure		Your Facility (100853)		All LCSR		All LCSR	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Abnormal Interpretation Rate, at annual exam (%)		10.57	8958 / 84769	10.59	29899 / 282316	10.69	35424 / 331240
Cancer Detection Rate (CDR) per 1000		NA	0 / 176790	0.00	0 / 589288	3.04	2002 / 659558
	prevalent cancers, detected at baseline exam	NA	0 / 88036	0.00	0 / 293476	3.71	1168 / 315095
	incident cancers, detected at annual exam	NA	0 / 84769	0.00	0 / 282316	2.70	893 / 331240
	stage 0	NA	NA / 423	13	NA / 1427	19	NA / 2094
	stage IA, IA1, IA2, IA3, IB	36.64	155 / 423	36.02	514 / 1427	39.35	824 / 2094
	stage IIA, IIB	7.57	32 / 423	7.78	111 / 1427	8.21	172 / 2094
	stage IIIA, IIIB, IIIC	14.66	62 / 423	14.72	210 / 1427	14.14	296 / 2094
	stage IV, IVA, IVB	10.17	43 / 423	9.39	134 / 1427	9.41	197 / 2094
	stage unknown	29.79	126 / 423	31.18	445 / 1427	27.98	586 / 2094
	presumptive case	NA	0 / 176790	0.00	0 / 589288	65.31	2089 / 659558
Positive Predictive Value 1 (PPV1)(%)		NA	0 / 24032	0.00	0 / 80355	2.24	2002 / 89526
	lung cancers detected on percutaneous biopsies (%)	NA	0 / 339	0.00	0 / 1080	59.68	894 / 1498
	lung cancers detected on bronchoscopies (%)	38.02	100 / 263	37.78	340 / 900	49.50	548 / 1107
	surgically detected lung cancers (%)	NA	0 / 186	0.00	0 / 551	81.54	786 / 964
Positive Predictive Value 2a (PPV2a) (%)		NA	0 / 19560	0.00	0 / 65498	0.74	538 / 72801
Positive Predictive Value 2b (PPV2b) (%)		NA	0 / 4472	0.00	0 / 14857	8.75	1464 / 16725
Positive Predictive Value 3 (PPV3) (%)		NA	0 / 523	0.00	0 / 1710	65.31	1408 / 2156

Facility 100853 Regional Comparison
Jan-Sep 2021

		2021							
Measure		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	176790	.	233844	.	125117	.	
Appropriateness of screening by USPSTF criteria (%)		88.08	155716 / 176790	87.52	204669 / 233844	87.12	109005 / 125117		
Smoking cessation counselling offered (%)		73.74	130357 / 176790	71.78	167852 / 233844	74.79	93576 / 125117		
	counselling offered among current smokers (%)	80.02	82660 / 103296	78.42	105520 / 134563	79.61	58675 / 73705		
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.44	NA / 175273	3.66	NA / 231899	2.92	NA / 123990		
	underweight (BMI <18.5)(mGy)	2.44	NA / 4786	2.54	NA / 6021	1.97	NA / 2878		
	normal (BMI of 18.5-24.9)(mGy)	2.76	NA / 40481	2.79	NA / 55174	2.30	NA / 30548		
	overweight (BMI of 25-29.9)(mGy)	3.20	NA / 54457	3.36	NA / 73226	2.70	NA / 40372		
	obese (BMI 30 or more)(mGy)	4.14	NA / 65888	4.53	NA / 85669	3.61	NA / 43683		
	obese class I (BMI of 30-34.9)(mGy)	3.80	NA / 36783	4.16	NA / 48265	3.27	NA / 25099		
	obese class II (BMI of 35-39.9)(mGy)	3.93	NA / 16688	4.26	NA / 21793	3.34	NA / 10763		
	obese class III (BMI of 40 or greater)(mGy)	4.27	NA / 12417	4.88	NA / 15611	3.88	NA / 7821		
	routine chest exam (mGy)	4.63	NA / 1672	3.77	NA / 3389	7.90	NA / 839		
	low dose CT chest exam (mGy)	3.43	NA / 172604	3.66	NA / 227924	2.89	NA / 122263		
Radiation exposure - Mean DLP	Overall	93.90	NA / 175264	93.75	NA / 231741	93.22	NA / 123847		
	underweight (BMI <18.5)(mGy-cm)	71.20	NA / 4786	69.14	NA / 6019	69.71	NA / 2876		
	normal (BMI of 18.5-24.9)(mGy-cm)	75.83	NA / 40482	75.73	NA / 55168	75.89	NA / 30513		
	overweight (BMI of 25-29.9)(mGy-cm)	88.00	NA / 54459	87.96	NA / 73236	89.06	NA / 40347		
	obese (BMI of 30 or more)(mGy-cm)	111.28	NA / 65877	110.53	NA / 85622	111.35	NA / 43647		
	obese class I (BMI of 30-34.9)(mGy-cm)	103.43	NA / 36775	102.37	NA / 48231	105.58	NA / 25082		
	obese class II (BMI of 35-39.9)(mGy-cm)	115.47	NA / 16682	115.43	NA / 21783	115.74	NA / 10756		

Facility 100853 Regional Comparison
Jan-Sep 2021

		2021							
Measure		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
	obese class III (BMI of 40 or greater)(mGy-cm)	128.00	NA / 12420	127.98	NA / 15608	122.91	NA / 7809		
	routine chest exam (mGy-cm)	162.30	NA / 1676	124.42	NA / 3394	285.59	NA / 839		
	low dose CT chest exam (mGy-cm)	93.19	NA / 172592	93.30	NA / 227761	91.93	NA / 122120		
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	13.59	24032 / 176790	13.03	30476 / 233844	14.08	17614 / 125117		
	Abnormal Interpretation Rate, at baseline exam (%)	16.51	14539 / 88036	15.61	17818 / 114110	16.65	10922 / 65586		
	Abnormal Interpretation Rate, at annual exam (%)	10.57	8958 / 84769	10.37	11709 / 112879	11.08	6357 / 57370		
Cancer Detection Rate (CDR) per 1000		NA	0 / 176790	0.00	0 / 233844	0.00	0 / 125117		
	prevalent cancers, detected at baseline exam	NA	0 / 88036	0.00	0 / 114110	0.00	0 / 65586		
	incident cancers, detected at annual exam	NA	0 / 84769	0.00	0 / 112879	0.00	0 / 57370		
	stage 0	NA	NA / 423	6	NA / 562	0	NA / 171		
	stage IA, IA1, IA2, IA3, IB	36.64	155 / 423	37.90	213 / 562	33.92	58 / 171		
	stage IIA, IIB	7.57	32 / 423	9.43	53 / 562	7.02	12 / 171		
	stage IIIA, IIIB, IIIC	14.66	62 / 423	16.73	94 / 562	11.11	19 / 171		
	stage IV, IVA, IVB	10.17	43 / 423	10.68	60 / 562	11.70	20 / 171		
	stage unknown	29.79	126 / 423	24.20	136 / 562	36.26	62 / 171		
	presumptive case	NA	0 / 176790	0.00	0 / 233844	0.00	0 / 125117		
Positive Predictive Value 1 (PPV1)(%)		NA	0 / 24032	0.00	0 / 30476	0.00	0 / 17614		
	lung cancers detected on percutaneous biopsies (%)	NA	0 / 339	0.00	0 / 372	0.00	0 / 109		
	lung cancers detected on bronchoscopies (%)	38.02	100 / 263	40.15	157 / 391	32.48	38 / 117		
	surgically detected lung cancers (%)	NA	0 / 186	0.00	0 / 253	0.00	0 / 72		

Facility 100853 Regional Comparison
Jan-Sep 2021

Measure		2021							
		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Positive Predictive Value 2a (PPV2a) (%)		NA	0 / 19560	0.00	0 / 24709	0.00	0 / 14518		
Positive Predictive Value 2b (PPV2b) (%)		NA	0 / 4472	0.00	0 / 5767	0.00	0 / 3096		
Positive Predictive Value 3 (PPV3) (%)		NA	0 / 523	0.00	0 / 662	0.00	0 / 217		

Section 2 Facility Report: Exams performed during Jan-Dec 2020 with follow-up through Sep 2021

Facility 100853 National Comparison
Jan-Dec 2020 with follow-up through Sep 2021

		2020			
Measure		Your Facility (100853)		All LCSR	
		Rate	Num-Den	Rate	Num-Den
All Exams		.	197871	.	659558
Appropriateness of screening by USPSTF criteria (%)		91.21	180475 / 197871	91.19	601462 / 659558
Smoking cessation counselling offered (%)		75.34	149083 / 197871	75.24	496278 / 659558
	counselling offered among current smokers (%)	81.90	92656 / 113130	81.73	307414 / 376131
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.35	NA / 195271	3.34	NA / 650910
	underweight (BMI <18.5)(mGy)	2.49	NA / 4821	2.47	NA / 15753
	normal (BMI of 18.5-24.9)(mGy)	2.64	NA / 46275	2.61	NA / 154108
	overweight (BMI of 25-29.9)(mGy)	3.10	NA / 61932	3.14	NA / 205649
	obese (BMI 30 or more)(mGy)	4.11	NA / 71983	4.08	NA / 241145
	obese class I (BMI of 30-34.9)(mGy)	3.75	NA / 40946	3.76	NA / 137061
	obese class II (BMI of 35-39.9)(mGy)	3.71	NA / 18407	3.76	NA / 61708
	obese class III (BMI of 40 or greater)(mGy)	4.68	NA / 12630	4.35	NA / 42376
	routine chest exam (mGy)	4.98	NA / 2764	4.67	NA / 9229
	low dose CT chest exam (mGy)	3.33	NA / 191393	3.33	NA / 637989
Radiation exposure - Mean DLP	Overall	94.55	NA / 195486	94.67	NA / 651692
	underweight (BMI <18.5)(mGy-cm)	71.82	NA / 4834	70.50	NA / 15790
	normal (BMI of 18.5-24.9)(mGy-cm)	76.59	NA / 46338	76.77	NA / 154337
	overweight (BMI of 25-29.9)(mGy-cm)	89.68	NA / 62009	89.30	NA / 205891
	obese (BMI of 30 or more)(mGy-cm)	111.88	NA / 72055	112.19	NA / 241382
	obese class I (BMI of 30-34.9)(mGy-cm)	1.00	NA / 40990	1.00	NA / 137212
	obese class II (BMI of 35-39.9)(mGy-cm)	1.00	NA / 18424	1.00	NA / 61760
	obese class III (BMI of 40 or greater)(mGy-cm)	130.00	NA / 12641	129.71	NA / 42410
	routine chest exam (mGy-cm)	139.46	NA / 2775	141.85	NA / 9255
	low dose CT chest exam (mGy-cm)	93.91	NA / 191597	94.00	NA / 638746
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	13.55	26818 / 197871	13.57	89526 / 659558
	Abnormal Interpretation Rate, at baseline exam (%)	16.68	15736 / 94330	16.58	52230 / 315095

Facility 100853 National Comparison
Jan-Dec 2020 with follow-up through Sep 2021

		2020			
Measure		Your Facility (100853)		All LCSR	
		Rate	Num-Den	Rate	Num-Den
	Abnormal Interpretation Rate, at annual exam (%)	10.55	10498 / 99533	10.69	35424 / 331240
Cancer Detection Rate (CDR) per 1000		2.88	569 / 197871	3.04	2002 / 659558
	prevalent cancers, detected at baseline exam	3.47	327 / 94330	3.71	1168 / 315095
	incident cancers, detected at annual exam	2.58	257 / 99533	2.70	893 / 331240
	stage 0	NA	NA / 587	19	NA / 2094
	stage IA, IA1, IA2, IA3, IB	42.42	249 / 587	39.35	824 / 2094
	stage IIA, IIB	7.67	45 / 587	8.21	172 / 2094
	stage IIIA, IIIB, IIIC	11.07	65 / 587	14.14	296 / 2094
	stage IV, IVA, IVB	9.03	53 / 587	9.41	197 / 2094
	stage unknown	28.62	168 / 587	27.98	586 / 2094
	presumptive case	63.71	590 / 197871	65.31	2089 / 659558
Positive Predictive Value 1 (PPV1)(%)		2.12	569 / 26818	2.24	2002 / 89526
	lung cancers detected on percutaneous biopsies (%)	61.75	268 / 434	59.68	894 / 1498
	lung cancers detected on bronchoscopies (%)	46.20	146 / 316	49.50	548 / 1107
	surgically detected lung cancers (%)	80.38	213 / 265	81.54	786 / 964
Positive Predictive Value 2a (PPV2a) (%)		0.69	151 / 21775	0.74	538 / 72801
Positive Predictive Value 2b (PPV2b) (%)		8.29	418 / 5043	8.75	1464 / 16725
Positive Predictive Value 3 (PPV3) (%)		63.71	402 / 631	65.31	1408 / 2156

Facility 100853: Regional Comparison
Jan-Dec 2020 with follow-up through Sep 2021

Measure		2020							
		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	197871	.	267380	.	142812	.	
Appropriateness of screening by USPSTF criteria (%)		91.21	180475 / 197871	90.71	242539 / 267380	89.37	127628 / 142812		
Smoking cessation counselling offered (%)		75.34	149083 / 197871	74.27	198572 / 267380	75.83	108292 / 142812		
	counselling offered among current smokers (%)	81.90	92656 / 113130	80.61	120447 / 149417	81.39	65662 / 80675		
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.35	NA / 195271	3.50	NA / 264273	2.94	NA / 139913		
	underweight (BMI <18.5)(mGy)	2.49	NA / 4821	2.47	NA / 6272	2.08	NA / 3215		
	normal (BMI of 18.5-24.9)(mGy)	2.64	NA / 46275	2.73	NA / 63822	2.36	NA / 35021		
	overweight (BMI of 25-29.9)(mGy)	3.10	NA / 61932	3.25	NA / 84058	2.78	NA / 45838		
	obese (BMI 30 or more)(mGy)	4.11	NA / 71983	4.35	NA / 95983	3.55	NA / 48711		
	obese class I (BMI of 30-34.9)(mGy)	3.75	NA / 40946	3.98	NA / 54820	3.32	NA / 28348		
	obese class II (BMI of 35-39.9)(mGy)	3.71	NA / 18407	4.04	NA / 24297	3.20	NA / 11735		
	obese class III (BMI of 40 or greater)(mGy)	4.68	NA / 12630	4.77	NA / 16866	3.59	NA / 8628		
	routine chest exam (mGy)	4.98	NA / 2764	4.15	NA / 5101	4.16	NA / 1178		
	low dose CT chest exam (mGy)	3.33	NA / 191393	3.49	NA / 258618	2.93	NA / 137476		
Radiation exposure - Mean DLP	Overall	94.55	NA / 195486	94.56	NA / 264500	93.59	NA / 139741		
	underweight (BMI <18.5)(mGy-cm)	71.82	NA / 4834	69.69	NA / 6291	70.23	NA / 3214		
	normal (BMI of 18.5-24.9)(mGy-cm)	76.59	NA / 46338	76.73	NA / 63930	77.38	NA / 35000		
	overweight (BMI of 25-29.9)(mGy-cm)	89.68	NA / 62009	89.36	NA / 84166	89.10	NA / 45811		
	obese (BMI of 30 or more)(mGy-cm)	111.88	NA / 72055	111.72	NA / 96099	110.80	NA / 48700		
	obese class I (BMI of 30-34.9)(mGy-cm)	1.00	NA / 40990	1.00	NA / 54888	1.00	NA / 28343		
	obese class II (BMI of 35-39.9)(mGy-cm)	1.00	NA / 18424	1.00	NA / 24330	1.00	NA / 11733		

Facility 100853: Regional Comparison
Jan-Dec 2020 with follow-up through Sep 2021

		2020							
Measure		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
	obese class III (BMI of 40 or greater)(mGy-cm)	130.00	NA / 12641	129.33	NA / 16881	124.42	NA / 8624		
	routine chest exam (mGy-cm)	139.46	NA / 2775	128.11	NA / 5109	136.25	NA / 1179		
	low dose CT chest exam (mGy-cm)	93.91	NA / 191597	93.89	NA / 258837	93.30	NA / 137303		
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	13.55	26818 / 197871	13.22	35359 / 267380	13.87	19809 / 142812		
	Abnormal Interpretation Rate, at baseline exam (%)	16.68	15736 / 94330	15.84	19971 / 126103	15.97	11562 / 72399		
	Abnormal Interpretation Rate, at annual exam (%)	10.55	10498 / 99533	10.76	14560 / 135263	11.43	7580 / 66337		
Cancer Detection Rate (CDR) per 1000		2.88	569 / 197871	2.91	779 / 267380	1.79	256 / 142812		
	prevalent cancers, detected at baseline exam	3.47	327 / 94330	3.43	433 / 126103	2.33	169 / 72399		
	incident cancers, detected at annual exam	2.58	257 / 99533	2.69	364 / 135263	1.51	100 / 66337		
	stage 0	NA	NA / 587	3	NA / 801	3	NA / 269		
	stage IA, IA1, IA2, IA3, IB	42.42	249 / 587	45.69	366 / 801	36.06	97 / 269		
	stage IIA, IIB	7.67	45 / 587	8.36	67 / 801	8.92	24 / 269		
	stage IIIA, IIIB, IIIC	11.07	65 / 587	13.98	112 / 801	11.90	32 / 269		
	stage IV, IVA, IVB	9.03	53 / 587	10.24	82 / 801	7.06	19 / 269		
	stage unknown	28.62	168 / 587	21.35	171 / 801	34.94	94 / 269		
	presumptive case	63.71	590 / 197871	65.20	803 / 267380	57.56	275 / 142812		
Positive Predictive Value 1 (PPV1)(%)		2.12	569 / 26818	2.20	779 / 35359	1.29	256 / 19809		
	lung cancers detected on percutaneous biopsies (%)	61.75	268 / 434	60.94	323 / 530	52.74	106 / 201		
	lung cancers detected on bronchoscopies (%)	46.20	146 / 316	47.73	210 / 440	42.52	54 / 127		
	surgically detected lung cancers (%)	80.38	213 / 265	82.14	345 / 420	81.54	106 / 130		

Facility 100853: Regional Comparison
Jan-Dec 2020 with follow-up through Sep 2021

Measure		2020							
		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Positive Predictive Value 2a (PPV2a) (%)		0.69	151 / 21775	0.78	224 / 28680	0.44	71 / 16281		
Positive Predictive Value 2b (PPV2b) (%)		8.29	418 / 5043	8.31	555 / 6679	5.24	185 / 3528		
Positive Predictive Value 3 (PPV3) (%)		63.71	402 / 631	65.20	534 / 819	57.56	179 / 311		

Maintenance of Certification (MOC): Practice Quality Improvement (PQI)

With the implementation of Continuous Certification and its annual look-back approach, diplomates must have completed at least one PQI Project or Participatory Quality Improvement Activity in the previous three years at each annual look-back. A PQI Project or Activity may be conducted repeatedly or continuously to meet PQI

requirements. (<https://www.theabr.org/diagnostic-radiology/maintenance-of-certification/improvement-medical-practice/participatory-activities>)

The National Radiology Data Registry has been approved by the American Board of Radiology for fulfilling MOC Part IV requirements. The names of the physicians are listed below.

NPI	Last Name	First Name
1013962497	Berland	Lincoln
1255433280	Thorwarth	William
1376568014	Geis	John
1740332030	Hillman	Bruce
1780697441	Rosen	Donald
1780766014	Cheng	Viola

Promote your participation in NRDR™!
Download your marketing toolkit today.

acr.org/LCSRtoolkit

CONTACT US

1.800.227.5463, ext. 3535
nrd@acr.org | nrd.acr.org

